Bidder Pharmaceutical: Abnormal fluctuations in stock trading; there are no major issues that should have been disclosed but were not.

Bidder Pharmaceuticals announced that on August 7 and August 10, 2026, the closing price fluctuation deviation of the companys stock exceeded 30% for two consecutive trading days, which constitutes an abnormal fluctuation. After internal review and inquiries with the controlling shareholder and actual controller, as of the announcement date, the company and related parties do not have any significant matters that should be disclosed but were not disclosed. Currently, production and operations are normal, and no media reports, market rumors, or trending concept matters that would have a significant impact on stock prices have been found. During this period, relevant personnel have not engaged in buying or selling the company's stock. Investors are reminded to pay attention to risks and to invest rationally.